$IBIO (132 days ago) - The LicKM-Subunit program (“IBIO-201”) was announced on June 3, 2020. (64 days ago) - Anti-SARS-CoV-2 spike titers to IBIO-201 were observed 21 days after immunization. Titers continued to increase over the 42-day study. Distinct, favorable Th1 and Th2 immune profiles were observed. This was announced on August 10, 2020. (35 days ago) - Was announced that Ibio had selected IBIO-201, its LicKM™-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. We plan to conduct more focused studies on each of IBIO-200 and IBIO-201, with the goal of advancing IBIO-201 to toxicology studies ahead of planned clinical development. Silence since then. Preclinical seems very thorough - Thats good ;) Updates are very positive regarding temporarily progress, but when can we expect to have a preclinical conclusion.? The 10-K obviously shows that money can´t speed up the process.